Skip to main content
. 2020 Jul 29;13:106. doi: 10.1186/s12920-020-00739-4

Table 2.

Results from targeted RNA sequencing using Archer™ FusionPlex™ Heme Panel version 1

Aberrationa Diagnosis Tissue FISH
(% cells)
Additional
method
Transcript Number of unique reads
(% of gene target)
Normal karyotype AML BM NA NA
MDS BM NA NA
t(8;21) AML BM 85% RUNX1-RUNX1T1 e6-e2 1414 (99%)
t(15;17) AML BM 56% RT-PCR PML-RARA e6-e3 337 (29%)
AML BM 22% RT-PCR PML-RARA e3-e3 206 (25%)
AML BM 89% RT-PCR PML-RARA e3-e3 110 (68%)
inv(16) AML BM 47% CBFB-MYH11 e5-e33 108 (62%)
t(1;22) AML PB NA RT-PCR RBM15-MKL1 e1-e4 442 (41%)
t(6;9) AML BM NA DEK-NUP214 e9-e18 298 (69%)
KMT2A-rearrangement KMT2A PTD AML BM NA SNP-array KMT2A e8e2 fusion 1024 (19%)
Unbalanced t(6;11) AML BM 83% (del(11q)) RT-PCR KMT2A-MLLT4 e8-e2 1538 (76%)
Unbalanced t(6;11) AML BM 80% (del(11q)) RT-PCR KMT2A-MLLT4 e8-e2 924 (92%)
t(11;19) AML BM 84% RT-PCR KMT2A-ELL e9-e2 337 (72%)
ins(10;11) AML BM 28% (del(11q)) KMT2A-MLLT10 e6-e15 86 (74%)
t(4;11) B-ALL BM 94% RT-PCR KMT2A-AFF1 e8-e4 785 (79%)
t(9;11) B-ALL PB 88% RT-PCR KMT2A-MLLT3 e8-e6 431 (44%)
del(11q23) B-ALL BM 87% RT-PCR KMT2A-ARHGEF12 e6-e22 1153 (90%)
t(11;19) T-ALL BM 41%b KMT2A-ENL e8-e2 313 (30%)
?t(11;22;11) T-ALL BM 73% RT-PCR KMT2A-CBL e7-e16 120 (59%)
t(9;22) AML (prev PV) PB 75% BCR-ABL1 e1-e3 408 (68%)
B-ALL BM 27% (atypical) RT-PCR BCR-ABL1 e13-e2 280 (45%)
t(12;21) B-ALL BM 86% RT-PCR ETV6-RUNX1 e5-e3 3215 (15%)
B-ALL BM 98% ETV6-RUNX1 e4-e3 5001 (34%)
t(1;19) B-ALL BM 56% RT-PCR TCF3-PBX1 e16-e3 6505 (30%)
del(1)(p32p32) T-ALL PB NA SNP-array STIL-TAL1 e1-e3 53 (10%)
del(4)(q12q12) MPN BM 48% FIP1L1-PDGFRA e13-e12 341 (76%)
t(5;12) MPN BM 87% ETV6-PDGFRB e7-e10 432 (97%)

aAberration according to results from chromosome analysis, FISH, RT-PCR and/or SNP-array

bThe gene fusion was also detected with a FISH probe specific for KMT2A-ENL fusion